10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
33 citations
,
January 2009 in “Contraception” Chlormadinone acetate is a strong, well-tolerated hormone used in birth control and hormone therapy with benefits for menstrual pain and skin conditions.
15 citations
,
August 2022 in “The Application of Clinical Genetics” ABCD1 gene mutations cause adrenomyeloneuropathy, leading to symptoms like limb weakness and spasticity, with management focusing on rehabilitation and spasticity treatment.
10 citations
,
October 2024 in “Dermatology Practical & Conceptual” Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
6 citations
,
January 2015 in “Journal of clinical & experimental dermatology research” The combination therapy may be more effective for mild alopecia areata, especially in patients with allergies.
November 2024 in “Dermatology Online Journal” Dupilumab may help treat alopecia areata, but more research is needed.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
November 2025 in “Skin Appendage Disorders” Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
February 2026 in “Journal of Drugs in Dermatology” Dupilumab helped a 13-year-old regrow hair after alopecia totalis.
November 2025 in “Biomedicines” JAK1 inhibitors can help reduce itchiness in atopic dermatitis.
4 citations
,
September 2011 in “American Journal of Clinical Dermatology” Ethinylestradiol/chlormadinone acetate may be an effective and well-tolerated treatment for skin conditions caused by excess androgens.